9782 related articles for article (PubMed ID: 17867596)
41. Growth inhibition of experimental non-Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN-238.
Keller G; Engel JB; Schally AV; Nagy A; Hammann B; Halmos G
Int J Cancer; 2005 May; 114(5):831-5. PubMed ID: 15609311
[TBL] [Abstract][Full Text] [Related]
42. Search for novel therapies for triple negative breast cancers (TNBC): analogs of luteinizing hormone-releasing hormone (LHRH) and growth hormone-releasing hormone (GHRH).
Buchholz S; Seitz S; Engel JB; Montero A; Ortmann O; Perez R; Block NL; Schally AV
Horm Mol Biol Clin Investig; 2012 Apr; 9(1):87-94. PubMed ID: 25961354
[TBL] [Abstract][Full Text] [Related]
43. Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines.
Westphalen S; Kotulla G; Kaiser F; Krauss W; Werning G; Elsasser HP; Nagy A; Schulz KD; Grundker C; Schally AV; Emons G
Int J Oncol; 2000 Nov; 17(5):1063-9. PubMed ID: 11029513
[TBL] [Abstract][Full Text] [Related]
44. [New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin].
Schally AV
An R Acad Nac Med (Madr); 2004; 121(3):493-500. PubMed ID: 15751842
[TBL] [Abstract][Full Text] [Related]
45. Rationally designed cyclic analogues of luteinizing hormone-releasing hormone: enhanced enzymatic stability and biological properties.
Laimou D; Katsila T; Matsoukas J; Schally A; Gkountelias K; Liapakis G; Tamvakopoulos C; Tselios T
Eur J Med Chem; 2012 Dec; 58():237-47. PubMed ID: 23127987
[TBL] [Abstract][Full Text] [Related]
46. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
Schubert A; Schulz H; Emons G; Gründker C
Gynecol Endocrinol; 2008 Jun; 24(6):331-8. PubMed ID: 18584413
[TBL] [Abstract][Full Text] [Related]
47. [Construction and expression of recombinant cecropin B-binding site of luteinizing hormone releasing hormone gene and its anticancer function].
Li XY; Li HL; Zheng GY
Zhonghua Fu Chan Ke Za Zhi; 2007 Jul; 42(7):477-81. PubMed ID: 17961339
[TBL] [Abstract][Full Text] [Related]
48. Increase of doxorubicin-induced apoptosis after knock-down of gonadotropin-releasing hormone receptor expression in human endometrial, ovarian and breast cancer cells.
Fister S; Schlotawa L; Günthert AR; Emons G; Gründker C
Gynecol Endocrinol; 2008 Jan; 24(1):24-9. PubMed ID: 17943530
[TBL] [Abstract][Full Text] [Related]
49. Experimental therapy of human endometrial cancers with a targeted cytotoxic bombesin analog AN-215: low induction of multidrug resistance proteins.
Engel JB; Schally AV; Halmos G; Baker B; Nagy A; Keller G
Eur J Cancer; 2005 Aug; 41(12):1824-30. PubMed ID: 16051478
[TBL] [Abstract][Full Text] [Related]
50. Dephosphorylation of cancer protein by tyrosine phosphatases in response to analogs of luteinizing hormone-releasing hormone and somatostatin.
Lee LT; Schally AV; Liebow C; Lee PP; Lee PH; Lee MT
Anticancer Res; 2008; 28(5A):2599-605. PubMed ID: 19035284
[TBL] [Abstract][Full Text] [Related]
51. Targeted Tubulysin B Hydrazide Conjugate for the Treatment of Luteinizing Hormone-Releasing Hormone Receptor-Positive Cancers.
Roy J; Kaake M; Srinivasarao M; Low PS
Bioconjug Chem; 2018 Jul; 29(7):2208-2214. PubMed ID: 29851465
[TBL] [Abstract][Full Text] [Related]
52. Luteinizing hormone-releasing hormone I (LHRH-I) and its metabolite in peripheral tissues.
Walters K; Wegorzewska IN; Chin YP; Parikh MG; Wu TJ
Exp Biol Med (Maywood); 2008 Feb; 233(2):123-30. PubMed ID: 18222967
[TBL] [Abstract][Full Text] [Related]
53. Antitumor effects of an imidazoquinoline in renal cell carcinoma.
Schwartz MJ; Liu H; Hwang DH; Kawamoto H; Scherr DS
Urology; 2009 May; 73(5):1156-62. PubMed ID: 19118885
[TBL] [Abstract][Full Text] [Related]
54. LHRH receptor expression in sarcomas of bone and soft tissue.
Deivaraju C; Temple HT; Block N; Robinson P; Schally AV
Horm Mol Biol Clin Investig; 2016 Nov; 28(2):105-111. PubMed ID: 27639272
[TBL] [Abstract][Full Text] [Related]
55. Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162.
Treszl A; Schally AV; Seitz S; Szalontay L; Rick FG; Szepeshazi K; Halmos G
Peptides; 2009 Sep; 30(9):1643-50. PubMed ID: 19524629
[TBL] [Abstract][Full Text] [Related]
56. Growth hormone in vascular pathology: neovascularization and expression of receptors is associated with cellular proliferation.
Lincoln DT; Singal PK; Al-Banaw A
Anticancer Res; 2007; 27(6B):4201-18. PubMed ID: 18225592
[TBL] [Abstract][Full Text] [Related]
57. [LHRH analogues for the treatment of prostate cancer: an evidence level-based analysis].
Pfitzenmaier J; Altwein JE
Aktuelle Urol; 2009 Mar; 40(2):100-8. PubMed ID: 19253209
[TBL] [Abstract][Full Text] [Related]
58. Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: a "smarter" chemotherapy.
Nagy A; Schally AV
Curr Pharm Des; 2005; 11(9):1167-80. PubMed ID: 15853664
[TBL] [Abstract][Full Text] [Related]
59. Sub-cellular accumulation of magnetic nanoparticles in breast tumors and metastases.
Zhou J; Leuschner C; Kumar C; Hormes JF; Soboyejo WO
Biomaterials; 2006 Mar; 27(9):2001-8. PubMed ID: 16280161
[TBL] [Abstract][Full Text] [Related]
60. Substantial expression of luteinizing hormone-releasing hormone (LHRH) receptor type I in human uveal melanoma.
Treszl A; Steiber Z; Schally AV; Block NL; Dezso B; Olah G; Rozsa B; Fodor K; Buglyo A; Gardi J; Berta A; Halmos G
Oncotarget; 2013 Oct; 4(10):1721-8. PubMed ID: 24077773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
